NICE is recruiting new members to independent advisory committees on the use of health technologies
NICE Appraisal for adalimumab, etanercept and infliximab for RA after failure of a previous anti-TNF
Document Actions
24 Nov 2008
We welcome the decision of the NICE appeal committee to recommend that the issue of sequential use be restarted as a full new appraisal, and look we forward to working with NICE to determine the most appropriate management of patients whose first anti-TNF does not work satisfactorily. We also welcome the recommendation of the Appeal committee that this should be done as soon as possible, as patients and clinicians have waited a considerable period of time for this important issue to be resolved.
Click here to view NICE’s statement: http://www.nice.org.uk/guidance/index.jsp?action=folder&o=42650
Debbie Smith, Head of External Relations and Clinical Affairs, BSR, November 2008